A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis

BACKGROUND: This study aimed to compare efficacy and safety of test-adalimumab (CinnoRA®, CinnaGen, Iran) to the innovator product (Humira®, AbbVie, USA) in adult patients with active rheumatoid arthritis (RA). METHODS: In this randomized, double-blind, active-controlled, non-inferiority trial, a to...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamshidi, Ahmadreza, Gharibdoost, Farhad, Vojdanian, Mahdi, Soroosh, Soosan G., Soroush, Mohsen, Ahmadzadeh, Arman, Nazarinia, Mohammad Ali, Mousavi, Mohammad, Karimzadeh, Hadi, Shakibi, Mohammad Reza, Rezaieyazdi, Zahra, Sahebari, Maryam, Hajiabbasi, Asghar, Ebrahimi, Ali Asghar, Mahjourian, Najmeh, Rashti, Amin Mohammadinejad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520357/
https://www.ncbi.nlm.nih.gov/pubmed/28728599
http://dx.doi.org/10.1186/s13075-017-1371-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520357/
https://www.ncbi.nlm.nih.gov/pubmed/28728599
http://dx.doi.org/10.1186/s13075-017-1371-4

Ejemplares similares